Literature DB >> 35436830

Five Times Reactivation of COVID-19 in a Patient with Thymoma.

Manoj Meena1, Krishnapriya S Kumar2, Govind Singh Rajawat1, Sumit Kumar Jain2.   

Abstract

BACKGROUND: The possibility of recurrence in COVID-19 is very rare and hence mostly underdiagnosed. In the face of pandemic, this can lead to circulation of the virus like a hidden iceberg. Better understanding about this topic can improve our knowledge of the COVID-19 pathogenesis and ways to control the transmission. CASE
PRESENTATION: A 41 year old male with no known comorbidities was admitted five times during a period of 7 months each time after being detected RTPCR positive for SARS-CoV-2 and more symptomatic than previously. He had no contact with other COVID-19 patients and was asymptomatic in between admissions. Despite this, he did not develop antibodies against SARSCoV-2. Later on, he was diagnosed with thymoma on biopsy of the anterior mediastinal mass. Patient's condition deteriorated on last hospitalization and he died, despite the treatment. Here we present an interesting report on multiple times recurrent COVID-19 infection, probably a case of reactivation and different plausible explanations on the role of thymoma.;
Conclusion: Acknowledging the potential of SARS-CoV-2 to cause recurrence is very important during the pandemic as a part of the long term transmission mitigation. The case report shows that previous infection does not guarantee complete immunity from COVID-19, especially in immuno-compromised patients. Hence, despite the status of prior infection, vulnerable individuals who recovered from COVID-19 should be under surveillance. © Journal of the Association of Physicians of India 2011.

Entities:  

Mesh:

Year:  2022        PMID: 35436830

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  1 in total

Review 1.  Reinfection and reactivation of SARS-CoV-2.

Authors:  Razieh Dowran; Amirmasoud Rayati Damavandi; Talat Mokhtari Azad
Journal:  Future Virol       Date:  2022-09-26       Impact factor: 3.015

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.